Superworth

Biomarin Pharmaceutical price to book ratio BMRN

Market value divided by the book value of the company's net assets, since 2010.

Today, Oct 23, 2026
1.7×
10-year median
3.7×
Against its 10-year history
3rd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.6× to 7.2×
Peer median
10.6×

Biomarin Pharmaceutical's price to book ratio is 1.7× as of Oct 23, 2026.

That is below its ten-year median of 3.7×, lower than on 97% of days in the last ten years.

Over that time it ranged from 1.6× in May 2026 to 7.2× in Jul 2020.

The median for 10 large drugmakers of a similar size is 10.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.7×1.6×2.1×
20251.9×1.6×2.4×
20242.4×2.2×3.7×
20233.7×3.1×4.8×
20224.2×3.2×4.4×
20213.8×3.2×4.0×
20203.9×3.4×7.2×
20195.0×4.0×6.0×
20185.1×4.8×6.5×
20175.6×5.1×6.0×
20165.4×4.8×8.3×
20157.4×6.6×13.4×
20148.9×5.6×9.2×
20137.7×6.2×8.6×
20125.8×4.6×6.5×
20115.1×3.7×5.4×
20104.7×4.4×6.7×

Against its peers

Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.

CompanyPrice to book ratio
BMRNBiomarin Pharmaceutical1.7×
CORTCorcept Therapeutics13.2×
PTGXProtagonist Therapeutics10.6×
JAZZJazz Pharmaceuticals2.9×
TGTXTG Therapeutics13.7×
ALKSAlkermes plc.4.0×
AMRXAmneal Pharmaceuticals197×
LGNDLigand Pharmaceuticals6.3×
KNSAKiniksa Pharmaceuticals International9.2×
INDVIndivior Pharmaceuticalsn/m
ARQTArcutis Biotherapeutics17.8×
Peer median10.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Biomarin Pharmaceutical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.